Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects-Reference-Cited by-同舟云学术

Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

Published:2014-01-13 Issue:3 Volume:20 Page:398-406
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Valentino L. A.¹,Rusen L.²,Elezovic I.³,Smith L. M.⁴,Korth-Bradley J. M.⁴,Rendo P.⁴

Affiliation:

1. Rush University Medical Center; Chicago IL USA

2. Institutul National de Hematologie Transfuzionala; Bucharest Romania

3. Medical Faculty; University of Belgrade; Clinic of Haematology; Clinical Center of Serbia; Belgrade Serbia

4. Pfizer Inc; Collegeville PA USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12344/fullpdf

Reference30 articles.

1. MASAC recommendation 170 concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) National Hemophilia Foundation 2007 http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=582

2. Delivery of treatment for haemophilia World Health Organization 2002 http://whqlibdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf

3. Guidelines for the management of hemophilia World Federation of Hemophilia 2005 http://www1.wfh.org/publication/files/pdf-1296.pdf

4. Guidelines for the management of hemophilia;Srivastava;Haemophilia,2013

5. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy;Rocca;Blood Transfus,2011

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study;European Journal of Haematology;2024-06-25

2. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors;Advances in Therapy;2024-04-23

3. Unresolved hemostasis issues in haemophilia;Haemophilia;2024-04

4. A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B;Journal of Blood Medicine;2024-03

5. Cost‐effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate–severe to severe hemophilia B in China;Pediatric Blood & Cancer;2023-02-23